OTI Joins MassBio and Cambridge Life Sciences Ecosystem

---

Massachusetts, USA [December 26th 2025]. Ophthalmic Therapeutic Innovation (OTI) is proud to join MassBio and Cambridge Scientific Lab as their membership, enabling deeper access to global innovation hub, world-class talent, translational expertise, and life science resources across Massachusetts. We extend our sincere thanks to Barbara Pearlman, CEO of Cambridge Scientific Labs (Watertown, MA), and Hawa Fall, PharmD, MBA, Manager of Business Development at Massachusetts Life Sciences Center for their welcoming OTI and invaluable support of our mission to end glaucoma blindness. 

OTI’s engagement with the Massachusetts life science community dates back to the height of the COVID-19 pandemic. At that time, OTI operated as a solo proprietary consulting enterprise and responded to MassBio’s COVID-19 Emergency Response, leading a UK–US strategic task force focused on emergency use of hydroxychloroquine (HCQ) therapeutic development and medical risk mitigation, in partnership with the NHS-UK, FDA, HHS-US, and industry partners including Novartis and Sanofi.

Our task force played a pivotal role in identifying overdose and misuse risks associated with hydroxychloroquine (oral) which ultimately had led to the withdraw of HCQ use (oral) by FDA and WHO. At very early on, we suggested the dexamethasone repurposing for COVID19 treatment, through UK RECOVERY Trial, which demonstrated that dexamethasone reduced mortality by approximately one-third in severely ill COVID-19 patients, collectively helping save countless lives during the spring of 2020.

We are deeply grateful to our core team members: Tina Guanting Qiu, MD, PhD (MA), Clive Wilson, PhD, (UK), Ian Catchpole, PhD (UK), Andy Dunden, MS (UK), David Cipolla (NY), and to an extraordinary extended network of 30–40 leading scientific and regulatory advisors, including Prof. Bob Langer (MIT), Dr. Wiley Chambers (FDA), Dr. Marco Zarbin,MD, Peter Kaiser, MD, Prof. John Marshall, Dr. Peter Kaiser, Dr. Julia Haller, Dr. Andrew Dick, Stan Miele, and Paul Hartung (MassBio)—as well as senior leaders across Novartis (Len Arsenault), BARDA, NHS, Sanofi (Paul Hudson), McLane Middleton, GSK, and GLG Social Impact.

As OTI advances its lead glaucoma program and expands its clinical and operational footprint, we look forward to contributing meaningfully to the MassBio community and the broader Massachusetts life science ecosystem—continuing our commitment to scientific rigor, cross-sector collaboration, and transformative patient impact.

Massachusetts, USA — [December 21st, 2025] — Ophthalmic Therapeutic Innovation (OTI), a clinical-stage ophthalmology company developing disease-modifying therapies for glaucoma, announced today the completion of a bridge financing with participation from two distinguished glaucoma specialists, Dr. Saya Nagori, MD, and Dr. Aman Shukairy, MD; Both have joined OTI's Clinical Advisory Board.

Both surgeon-investors are actively practicing glaucoma specialists with extensive first-hand experience treating patients with progressive and refractory glaucoma. Their investment reflects strong confidence in OTI-2024, patented, pre-Phase 3 small molecule adenosine drug, which is being developed as a first-in-class curative eye-drop for treating and preventing glaucomateous neural degeneration and clinically uncontrolled IOP through tissue rejuvenation.

“Having glaucoma surgeons invest in OTI is particularly meaningful,” said Tina Guanting Qiu, MD, PhD, EMBA, Founder and CEO of Ophthalmic Therapeutic Innovation. “Drs. Nagori and Shukairy deeply understand the unmet clinical needs in glaucoma care and recognize the potential of OTI-2024 to move beyond symptom relief IOP reduction toward long-term glaucoma disease control and visual field stability. Like anti-VEGF therapy for wet AMD, OTI-2024 derived MMP pathway based therapy is going to transform glaucoma patient care in decades to come”.

OTI-2024 (eye drops) is designed as a maintenance MMP therapy with following key features:

• IOP normalization & drug holiday with dosing flexibility.
• A breakthrough therapy with the potential to Stop glaucoma disease progression.

This differentiated approach aims to shift glaucoma treatment from continuous symptomatic management to sustained disease control.

Proceeds from the bridge financing will support continued intellectual property development, regulatory execution, and operational activities as OTI prepares for its next stage of institutional financing.

About Ophthalmic Therapeutic Innovation (OTI)
Ophthalmic Therapeutic Innovation is a clinical-stage biotechnology company focused on developing first/best-in-class, disease-modifying therapies for glaucoma. Its lead program, OTI-2024, aims to deliver a curative eye-drop therapy addressing long-term disease control and IOP stability.

November 25th 2025:  OTI had a FDA Type C meeting and received positive feedback on our plans for the reformulation CMC preclinical framework for the IND clearance towards Phase 3 pivotal clinical trials for glaucoma (no need to repeat Ph2 study), with the 3-month IOP endpoint confirmed. We are also working with FDA to redefine glaucoma study endpoint: IOP Normalization @6 months with dosing flexibility. If approved, OTI-2024 will be the first and only glaucoma eye drops that does not require to dose on time.

OTI-2024 -(rebirth of Trabodenoson) is the first/best in class adenosine small molecule eye drops with unique dual MoAs (IOP+Neuro/MMP), represents the first Curative therapy via tissue rejuvenation based on MMP pathway-based therapy for glaucoma. Our strategy is to develop OTI-2024 as an IOP normalization drug, a new MMP agent, which can address the pressing unmet needs: poor responders, poor compliance and unstoppable vision loss in glaucoma. Through MMP mainteinance therapy to stabilize the disease progression and hVF stability. Like anti-VEGF therapy for wet AMD, MMP (matrix metalloproteinase) pathway based therapy (maintenance) is a transformative medicine to patients with glaucoma. We are redefining glaucoma patient care by IOP normalization (in replacing the IOP reduction as sympton relief.

Massachusetts, USA — [September 30th, 2025] — Ophthalmic Therapeutic Innovation (OTI), a clinical-stage ophthalmology company advancing disease-modifying therapies for glaucoma, today announced that Catherine Grealy Cohen has joined OTI as a Strategic Board Advisor.

As OTI enters this season of renewal and growth, the company is turning a new page while advancing its lead glaucoma clinical development program, OTI-2024, an investigational new drug representing the rebirth of Trabodenoson. After three years of disciplined bootstrapping, OTI has transformed a previously failed IOP-lowering drug into a first-in-class, potentially curative therapy with a novel mechanism focused on tissue rejuvenation and long-term disease modification. OTI-2024 is designed to address the most pressing unmet needs in glaucoma care, including poor responders, poor treatment adherence, and unstoppable vision loss, while setting a new standard for durable disease control.

“Setting new standards in medicine is never easy,” said Tina Guanting Qiu, MD, PhD, Founder and CEO of OTI. “At this critical stage of our growth, we are honored to welcome Catherine Grealy Cohen to OTI. Her leadership and deep experience in health policy and ophthalmology advocacy will be instrumental in increasing OTI’s visibility among regulatory policymakers and the broader ophthalmology community.” Catherine Grealy Cohen brings decades of distinguished leadership in government relations, health policy, and ophthalmology advocacy. After 25 years leading the Washington, D.C. office of the American Academy of Ophthalmology.

“I am excited about OTI’s vision and its first curative solution for glaucoma,” said Catherine Grealy Cohen. “OTI is pioneering MMP-pathway–based therapy for glaucoma, with the potential to surpass the impact of anti-VEGF therapies by addressing both early- and late-stage glaucoma disease rate limiting root causes .”

Ms. Cohen previously served as Vice President and Senior Advisor to the American Academy of Ophthalmology, Director of Federal Affairs at Eastman Kodak, and Director of the Washington, D.C. office of the American Society of Clinical Pathologists.

She holds a Master’s degree in Health Services Administration (MHSA) from The George Washington University, is a Certified Association Executive, completed the Senior Managers in Government Program, Policy and Management at Harvard Kennedy School, and earned a BA in Political Science and Asian Studies from Regis College.

“On behalf of OTI, I thank our supporters, advisors, and partners for standing with us as we work to fulfill our mission,” Dr. Qiu added. “Together, we are committed to delivering a long-awaited cure and eradicating glaucoma-related blindness.

OTI is Building a High-Standard Governance Platform

As OTI prepare for the next stage of growth, we are establishing a robust corporate governance framework—including policies, rules, and a compliance system—that will ensure OTI operates with transparency, fairness, and accountability. This foundation will provide investors and partners with confidence that contributions are safeguarded and aligned with value creation.

In support of this, OTI have appointed Hugh P. Cam, PhD, EMBA, as Vice President of Operations and Corporate Secretary (recordkeeping capacity). Hugh is Harvard trained human genetic expert, has worked with OTI since last April, brings scientific acumen, startup entrepreneurial and management experience from MIT, with EMBA on finance accouting proficiency, and will play a pivotal role in ensuring our compliance and operational readiness.

Looking Ahead

With breakthrough science and high-standard corporate governance, OTI is positioned to attract top-tier investors and world-class board members. Our mission remains clear: to deliver the first curative therapy for refractory glaucoma, addressing an urgent unmet need for patients and transforming a market that has seen little innovation in 30 years.

Advanced our pioneering science: “We pioneer MMP pathway–based therapy via tissue rejuvenation that can reverse tissue damage causing vision loss in patients with glaucoma. Like anti-VEGF for retina, it’s transformative medicine.” – Dr. Tina Guanting Qiu, Founder & CEO.

Dear Friends, Colleagues and Advisors,

I’m Dr. Tina Guanting Qiu, MD, PhD, Founder and CEO of Ophthalmic Therapeutic Innovation (OTI) LLC. I am an ophthalmic surgeon and stem cell transplant biologist with over 25 years in the field—including roles at GSK, Inotek, Astellas and Lineage Cell—I pioneer in big data for drug discovery and development (“do it faster, cheaper and better”). Today, I’m thrilled to invite you to join our equity crowdfunding campaign on Wefunder.

Glaucoma is the No.1 leading cause of irreversible blindness, projected to affect 120 million by 2040 worldwide. One in three patients risks legal blindness, there is no cure. Current standard of care (eye drop, surgeries and laser) is of symptom relief IOP lowering, temporarily. OTI is going to change this.

Unlike many startups still in early phases with only ideas and prototypes, OTI holds a patented, derisked, late stage, clinically validated Curative asset addressing a multi-billion-dollar market. We are currently raising a minimum of $250K (part of a $3-4M raise milestone) to fund critical IP/legal & SG&A cost to advance our candidate to pivotal Phase 3 trials.

OTI's clinical sciences are vetted by top glaucoma experts: Drs Louis Cantor, Ike Ahmed and James Tsai. OTI's regulatory strategy is aligned with new FDA Priorities at big data frontier.

We’re raising $3.0M via Wefunder to:
- IP/legal fees and SG&A costs ($250K).
- GMP materials and In vitro formulation stability testing.
- In vivo formulation validation & rabbit IOP study on bioequivalence (new formula vs Inotek’s eye drop formula).

Your investment—starting at $100—could unlock this visibility and propel us toward Phase 3 pivotal trials.

👉 Invest today or learn more: 

https://wefunder.com/ophthalmic.therapeutic.innovation.llc

📎 Our website: https://lnkd.in/ewk6HhRM
🔗 Phase 3 insights: https://lnkd.in/dyNmptsK

Thank you for believing in our mission.

With gratitude,
Tina Guanting Qiu, MD PhD EMBA
qiu-tina@ophthalmic-innovation.com

Disclaimers:
We are "testing the waters" to gauge investor interest in an offering under Regulation Crowdfunding. No money or other consideration is being solicited. If sent, it will not be accepted. No offer to buy securities will be accepted. No part of the purchase price will be received until a Form C is filed and only through Wefunder’s platform. Any indication of interest involves no obligation or commitment of any kind..

July 11th 2025, OTI has been selected to present at 2025 Future Ophthalmology Forum -Europeon Forum as Private Company Showcase at on September 11, 2025 at Copenhagan, Demark. Prior, OTI has been participating Future Ophthalmology Forum since 2021, and made presentations as Private Company  Showcase in 2023 European Forum at Vienna, Austria, and 2024 European Forum at Bacelona, Spain. Video recordings: https://www.ophthalmology-futures.com/past-forums/

June  17th, 2025, I had the pleasure to attend FDA commissioner hosted CEO Forums in Boston during 2025 BIO Convention, along with ~120 CEOs and executive leaders from Massachussetts and the NE region. My big takehome message from the new administration is FDA's Priorities at big data frontier, FDA encourages biotech Pharma to leverage big data real world evidence for regulatory submission, which helps to reduce costs and accelerate medicine innovation, focusing on curative (doi: 10.1001/jama.2025.10116). At the forum, I had a chance to share my views about the need for increasing the bar for drug efficacy scruitiny at early stage clinical development. Traditionally, as long as a drug is safe, FDA gives a green light. This has to change with increased big data and AI tools. We are very appreciative of this informative and direct dialogues with Dr. Marty A. Makary, M.D., M.P.H and sharing our concerns, feedback and suggestions. OTI's big data strategy is aligned with FDA's real word evidence policy, OTI is a pioneer in leveraging big data to solve the biggest problems - 90% failure in medicine development.

The 21st century ushers us into an information explosive era in modern medicine development. At the cusp of biology and technology convergences, medical breakthroughs sprout from the tiding waves of big data surge in this ever-changing modern world.  In this special  edition of MDG Boston roundtable discussions, we have invited our special guests, Professor Robert Langer at MIT, and Dr Janet Woodcock, former acting FDA commissioner, and Chris Cowles, IP Expert, Partner at Whither & Bergman to dive into some of the most exciting new frontiers where “big data”  is help shaping the future landscape of regulatory, IP, platform technology and more.  Watch the recordings:  https://www.mdgboston.org/event/the-extraordinary-impact-of-big-data-on-biomedical-innovation-platfo